Combination therapy to prevent liver cancer recurrence after surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (bevacizumab) after surgery or ablation for liver cancer that has a high chance of coming back. The goal is to see if this treatment can reduce the risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have liver cancer that has been confirmed by biopsy or imaging tests.
- You must have had surgery or ablation that removed all visible cancer (confirmed by scan within 2 months).
- Your cancer must have at least one high-risk factor: a single tumor larger than 2 inches, 3 or more tumors, signs of blood vessel invasion, or a tumor grade of 3 or 4.
- Your liver function must be good (Child-Pugh score A) and you must be in good general health (ECOG score 0-1).
- You must have no active hepatitis B or C infection, or if you do, it must be well controlled with antivirals.
- You cannot have had any previous cancer treatment for this liver cancer other than surgery or ablation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new dual immunotherapy drug (QL1706) given before surgery to remove liver cancer. The goal is to reduce the chance the cancer comes back after surgery in patients with early-stage disease that has high risk of recurrence.
This study tests a combination of three treatments (HAIC, camrelizumab, and apatinib) given before and after surgery for early-stage liver cancer that has high risk of coming back. The goal is to reduce the chance of cancer recurrence and improve survival.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial tests a combination of liver-directed chemotherapy (HAIC), two immunotherapy drugs (iparomlimab and tuvonralimab), and bevacizumab (a drug that blocks blood vessel growth) in people with liver cancer that is too large or numerous for immediate surgery but might become removable after treatment. The goal is to shrink the tumor enough to allow surgery.
Hear when a new Adjuvant Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.